Postpartum Hemorrhage (PPH) - Comprehensive 2025/2026 Update

Definition (UPDATED 2025)

• At 500 mL threshold: sensitivity only 75.7% for predicting maternal mortality/severe morbidity
• At 300 mL + any abnormal hemodynamic sign: sensitivity improves to 86.9-87.9%

• Primary PPH: Within 24 hours of delivery (most common)
• Secondary PPH: 24 hours to 12 weeks postpartum

Epidemiology

• Affects millions of women annually worldwide
• Causes approximately 45,000 maternal deaths per year globally (WHO 2025)
• The leading cause of maternal mortality globally
• Even when non-fatal: leads to organ damage, hysterectomy, anxiety, PTSD
• Higher burden in low- and lower-middle-income countries

The "4 T's" - Causes / Etiology

Uterine Atony - Key Risk Factors

• Overdistended uterus (twins, polyhydramnios, macrosomia)
• Prolonged or augmented labor
• High parity (grand multiparity)
• Chorioamnionitis
• Uterine fibroids
• General anesthesia
• Rapid or precipitous labor

Placenta Accreta Spectrum (PAS)

• Increasingly prevalent due to rising cesarean rates
• Accreta (superficial) > Increta (into myometrium) > Percreta (through serosa)
• Requires specialized multidisciplinary team management

Diagnosis

Active Quantification of Blood Loss (QBL)

• The 2025 WHO consolidated guidelines strongly recommend using calibrated collection drapes for objective blood measurement at every delivery
• Visual estimation underestimates blood loss by 30-50%
• QBL is now a standard of care recommendation

NEW 2025 Diagnostic Algorithm (WHO/FIGO/ICM)

• Blood loss ≥500 mL alone, OR
• Blood loss ≥300 mL + any of:
  • Pulse >100 bpm
  • Systolic BP <100 mmHg
  • Diastolic BP <60 mmHg
  • Shock index >1.0

Assessment tools

• Shock Index (HR/SBP): >1.0 indicates significant hemorrhage
• Bimanual examination: Assess uterine tone, laceration source
• Ultrasound: Detect retained placental fragments, uterine wall integrity
• Labs: CBC, coagulation panel (PT, APTT, fibrinogen), crossmatch
• Viscoelastic testing (TEG/ROTEM): 2025 multidisciplinary consensus now formally endorses routine integration into obstetric transfusion protocols for goal-directed hemostatic management

THE MOTIVE BUNDLE (NEW 2025 - WHO/FIGO/ICM)

Prevention - Active Management of Third Stage of Labor (AMTSL)

Uterotonic Prophylaxis (2025 Cochrane Network Meta-Analysis, PMID 40237648 - 122 trials, 121,931 women)

1. Ergometrine + Oxytocin combination - highest ranked; RR 0.76 (95% CI 0.64-0.90) vs oxytocin alone for PPH ≥500 mL (high-certainty evidence)
2. Misoprostol + Oxytocin combination - RR 0.70 (95% CI 0.57-0.87) vs oxytocin alone (moderate-certainty)
3. Oxytocin 10 IU IM/IV - remains WHO first-line standard; preferred over misoprostol alone
4. Carbetocin - similar effectiveness to oxytocin (high-certainty evidence); preferred when cold chain unavailable (heat-stable formulation)
5. Ergometrine alone - similar to oxytocin but more side effects
6. Misoprostol alone - when oxytocin unavailable (community settings)

Other AMTSL components

• Controlled cord traction (after signs of placental separation)
• Uterine massage after placental delivery
• Early skin-to-skin + breastfeeding (promotes endogenous oxytocin)

Treatment - Stepwise Approach

Step 1: Immediate Resuscitation

• Call for help - activate PPH protocol/massive transfusion protocol early
• Large-bore IV access (×2), send blood for grouping and crossmatch
• IV fluid resuscitation - Lactated Ringer's solution preferred
• Oxygen supplementation
• Urinary catheter (monitor output)
• Keep patient warm (prevent hypothermia-coagulopathy-acidosis triad)

Step 2: Uterotonics (First-Line)

• 20-30 units in 1000 mL IV fluid, infusion rate ≤100 mU/min
• Do NOT give as IV bolus (risk of hypotension, especially in hemorrhage)
• Bolus injections should be specifically avoided due to risk of cardiovascular collapse

• 0.2 mg IM (preferred route)
• NOT IV - risk of severe hypertension, CNS vasospasm, stroke
• Contraindicated in hypertension, preeclampsia, cardiovascular disease

• 250 µg IM, can repeat; maximum 8 doses
• Use with caution/avoid in asthma, cardiovascular disease
• Effective for refractory atony

• 800-1000 µg rectally or sublingually for refractory hemorrhage
• Useful when injectable uterotonics fail
• Effective in resource-limited settings

Step 3: Tranexamic Acid (TXA) - KEY UPDATE

• 1 g IV over 10 minutes
• Second dose of 1 g if bleeding continues after 30 minutes, or recurs within 24 hours
• Must be given within 3 hours of birth (efficacy lost after 3 hours)
• Safe - does not increase thromboembolism risk in PPH populations (Goldman-Cecil textbook)

Step 4: Non-Surgical Hemorrhage Control Devices

• Bakri balloon: fill with 300-500 mL saline; first-line tamponade device
• "Positive tamponade test" = cessation of bleeding suggests surgical management may be avoidable
• Condom catheter UBT: effective low-cost alternative in resource-limited settings
• Foley catheter: useful for low-lying placental site bleeding

• Compresses lower body to redistribute blood to vital organs
• Useful during transport in resource-limited settings

• Sterile gauze; retrospective evidence supports use in atony where other measures fail

• Highly effective (success rate ~85-95%) where interventional radiology is available
• Uterine preservation possible; subsequent pregnancies reported after procedure

Step 5: Surgical Management

Uterine compression sutures (uterus-conserving)

• B-Lynch suture: "Brace" technique encircling the uterus compressing the blood supply
• Hayman suture: Simpler variant of brace suturing
• Both allow future fertility preservation

Arterial Ligation

1. O'Leary uterine artery ligation (bilateral)
2. Hypogastric (internal iliac) artery ligation - if uterine artery ligation fails
   • Relies on transient decrease in regional blood pressure/flow
   • Collateral circulation preserved - no long-term consequence
   • Subsequent successful pregnancies reported

Hysterectomy (Peripartum Hysterectomy)

• Last resort for life-threatening, uncontrolled hemorrhage
• Emergency: total or subtotal (cervix-sparing) hysterectomy
• Definitive in placenta accreta spectrum

Blood Product Transfusion (2025 Update)

Red Blood Cell (RBC) Transfusion

• Transfuse when Hb <7 g/dL in actively bleeding patients
• In obstetric patients, lower threshold of 6.0 g/dL generally accepted
• With cardiovascular instability: threshold of 6.5 g/dL
• Asymptomatic, hemodynamically stable patients with low Hb: reassess at 48h post-delivery if blood loss >1000 mL

Massive Transfusion Protocol (MTP)

• Early activation when blood loss ≥1500 mL or ongoing hemorrhage
• Fixed-ratio transfusion: 1:1:1 (RBC:FFP:Platelets) - mirrors whole blood composition
• Target: fibrinogen >2 g/L (critical in PPH - fibrinogen drops early and significantly)
• Fibrinogen concentrate (2-4 g IV) or cryoprecipitate when fibrinogen <2 g/L
• Cell salvage (intraoperative autotransfusion) during cesarean/laparotomy

TEG/ROTEM Goal-Directed Therapy

• 2025 consensus formally endorses viscoelastic testing in obstetric protocols
• Guides specific factor replacement (fibrinogen, platelets, FFP)
• Reduces unnecessary transfusions vs empirical fixed-ratio approach
• Key limitation: high equipment cost, not universally available

Special Situations

Uterine Inversion

• Rare but acute emergency - recognize by inability to palpate fundus abdominally
• Immediate manual reinversion (Johnson maneuver) before uterus hardens
• Tocolysis first (if cervical ring contracted): IV magnesium sulfate, β-mimetics (terbutaline), nitroglycerin
• If manual fails under tocolysis: general anesthesia for relaxation + reinversion
• Do NOT give uterotonics until uterus is reinverted (will worsen entrapment)
• After reinversion: oxytocin infusion to maintain tone

DIC in PPH

• Can be cause OR consequence of PPH
• Early recognition: declining fibrinogen (most sensitive early marker), prolonged PT/APTT
• Treat underlying cause + replace consumed factors
• Cryoprecipitate/fibrinogen concentrate + FFP + platelets as needed

Placenta Accreta Spectrum (PAS)

• Prenatal diagnosis by US/MRI allows planned delivery at tertiary center
• Multidisciplinary team: obstetrics, urology, vascular surgery, IR, hematology
• Planned cesarean hysterectomy at 34-36 weeks (placenta left in situ)
• UAE/balloon occlusion of internal iliac arteries may be placed prophylactically

Anemia in Pregnancy/PPH Prevention

• WHO 2025 emphasizes antenatal anemia correction to reduce PPH risk and severity
• Daily oral iron + folate in all pregnant women
• IV iron (Cochrane 2024, PMID 39651609) for rapid correction when oral inadequate
• Post-PPH: reassess Hb at 48h if blood loss >1000 mL; IV iron for iron deficiency anemia post-PPH

Monitoring & Escalation

• Central venous pressure (CVP) line or Swan-Ganz catheter for extensive hemorrhage
• Facilitates accurate cardiovascular monitoring, avoids pulmonary edema from over-hydration

• Hemodynamic instability despite initial measures
• Ongoing blood loss >150 mL/min
• Need for >4 units RBC in 4 hours
• Failure of uterotonic therapy after 2 agents
• Any of above → escalate to surgical/interventional options immediately

2025 WHO Consolidated Guidelines - Key Highlights

• 51 evidence-based recommendations - the first consolidated PPH-specific global guideline
• Part of the Global Roadmap to Combat PPH 2023-2030
• Key shifts from previous guidance:
  1. Lower diagnostic threshold (300 mL + vital signs vs 500 mL alone)
  2. MOTIVE bundle as immediate treatment framework
  3. QBL with calibrated drapes as standard of care
  4. Antenatal anemia prevention as core strategy
  5. Stronger emphasis on IV iron for anaemia correction
  6. TXA as concurrent first-line (not rescue) therapy in treatment bundle

Summary Algorithm

Birth → Active QBL with calibrated drape
         ↓
    Blood loss ≥500 mL  OR  ≥300 mL + abnormal vital signs
         ↓
    Activate PPH protocol → Call for help
         ↓
    MOTIVE Bundle simultaneously:
    M - Bimanual uterine massage
    O - Oxytocin 20-30U IV infusion (NOT bolus)
    T - TXA 1g IV within 3 hours
    I - IV fluids (Lactated Ringer's)
    V - Examine vagina/cervix/uterus (rule out lacerations, retained tissue)
    E - Escalate if no response in 15-30 min
         ↓
    Add 2nd/3rd uterotonic: Ergometrine → Carboprost → Misoprostol
         ↓
    Balloon tamponade (Bakri) / Uterine packing / UAE
         ↓
    Laparotomy: B-Lynch suture → Uterine artery ligation → Hysterectomy

Key Recent Evidence Summary

Definition of PPH - WHO/FIGO/ICM 2025 Update

Traditional Definition (Pre-2025)

• Blood loss ≥500 mL within 24 hours after vaginal delivery
• Blood loss ≥1000 mL after cesarean section
• This was the single threshold used globally for decades

NEW WHO 2025 Definition (October 5, 2025)

Criterion A (unchanged):

Blood loss ≥500 mL within 24 hours of delivery (any mode)

Criterion B (NEW - the key update):

Blood loss ≥300 mL + ANY abnormal vital sign

• Pulse rate >100 bpm
• Systolic BP <100 mmHg
• Diastolic BP <60 mmHg
• Shock index >1.0 (HR ÷ systolic BP)

Why the threshold was lowered - The Evidence

Classification by Timing

Key Practical Implication of the New Definition

Bottom line: WHO 2025 says - do not wait for 500 mL if the patient has ANY sign of haemodynamic compromise. Act at 300 mL + one abnormal vital sign.